Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported second quarter 2021 net revenues of $9.1 million, with total revenues for the first half reaching $19.6 million, a 9.3% increase from 2020. The company achieved a net income of $1.4 million year-to-date, rebounding from a loss of $2 million in the previous year. Despite a slight decline from Q2 2020, total operating expenses decreased to $10.5 million. Cumberland's financial health includes $89 million in total assets and $48 million in shareholders' equity. The company is committed to improving patient care through its diverse product portfolio.
Cumberland Pharmaceuticals (CPIX) will release its second quarter 2021 financial results on August 10, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company specializes in branded prescription products for hospital acute care, gastroenterology, and rheumatoid arthritis. Its FDA-approved portfolio includes Acetadote and Caldolor, among others. Cumberland is also advancing Phase II clinical programs in various therapeutic areas.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) released its 2020 Sustainability Report, highlighting significant achievements in environmental, social, and governance (ESG) matters. The company safely delivered 2.5 million patient doses, managed over 4,000 pounds of expired products, and reported no product recalls or FDA safety issues. The report emphasizes Cumberland's commitment to sustainability, with initiatives like drug serialization to combat counterfeiting. The workforce comprises 46% women and 18% minorities, showcasing its focus on diversity and employee development.
Cumberland Pharmaceuticals (NASDAQ: CPIX) released case reports detailing the effectiveness of Vibativ (telavancin) in treating secondary bacterial infections in COVID-19 patients, especially those with pre-existing health conditions such as obesity, diabetes, and heart disease. The reports include five instances where Vibativ effectively treated hospital-acquired and ventilator-associated bacterial pneumonia, resulting from serious staph infections. The timely use of Vibativ has shown to improve patient outcomes significantly, showcasing its potential in combating these severe infections.
Cumberland Pharmaceuticals (NASDAQ: CPIX) has announced the promotion of John Hamm to Director of Finance & Accounting and Chief Financial Officer. With over 25 years of experience, including 20 in health care, Hamm will oversee finance, accounting, and corporate development activities. Previously the Director of Corporate Development, Hamm has been integral to the company since 2019. CEO A.J. Kazimi expressed confidence in Hamm's leadership to enhance patient care through quality medicines. Cumberland develops and commercializes approved pharmaceutical brands in acute care, gastroenterology, and rheumatology.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported a 26.5% increase in net revenues to $10.5 million for Q1 2021. The company also generated an additional $500,000 from divested product rights. Key products contributed significantly, with Vibativ® earning $5.1 million. Operating expenses rose to $10.9 million, influenced by higher costs from Vibativ sales. Net income was $0.2 million, representing a turnaround from a loss of $1.1 million the previous year. The financial position included $93 million in total assets and $47 million in shareholders' equity.
Cumberland Pharmaceuticals (NASDAQ: CPIX) will release its Q1 2021 financial results and company update on May 11, 2021, post-market. A conference call will follow at 4:30 p.m. ET. The company focuses on high-quality prescription brands for hospital acute care and gastroenterology. Its FDA-approved product portfolio includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, Vibativ, and RediTrex. The firm is also advancing Phase II clinical programs for ifetroban targeting various diseases.
Cumberland Pharmaceuticals Inc. (CPIX) reported a strong performance for Q4 and full-year 2020, highlighting net revenues of $10.3 million in Q4, a 10% year-over-year increase, and totals of $37.4 million for the year, up 9% from 2019. The company also recognized $3.2 million in revenue from divested product rights. Total assets stood at $96.5 million, with cash and investments of $24.8 million. The firm launched new formulations for its Caldolor product, helped hospitals during the pandemic, and plans to expand its RediTrex line in 2021.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its fourth quarter and annual 2020 financial results after the market closes on March 9, 2021. A conference call will take place the same day at 4:30 p.m. Eastern Time to discuss these results. The company focuses on specialty pharmaceuticals, offering several FDA-approved products that target acute care, gastroenterology, and oncology markets. Additionally, Cumberland has ongoing Phase II clinical programs for its ifetroban product candidates aimed at treating conditions like Duchenne Muscular Dystrophy.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the launch of RediTrex® (methotrexate) injection, a pre-filled syringe system aimed at improving the ease and accuracy of methotrexate administration for patients with arthritis and psoriasis. RediTrex is FDA approved for severe rheumatoid arthritis and psoriasis patients who struggle with oral methotrexate. It features a retractable needle and user-friendly design, reducing pain and confusion compared to existing options. The launch is slated for two phases, beginning with select centers and expanding nationally in Q1 2021.